Regeneron said on Friday the U.S. Food and Drug Administration has once again declined to approve its blood cancer therapy, ...

August 1, 2025Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $12.89, expectations were $8.43.

Pharmaceutical stocks slumped after President Donald Trump sent letters to 17 drugmakers with an ultimatum to reduce drug ...

An extension of a pivotal phase 3 trial shows that the functional and anatomic benefits of Eylea HD (aflibercept 8 milligram dose) have staying power in people with neovascular (wet) age-related ...

Fluid resolution at week 4 seems to translate into longer dosing intervals at week 96 of the PULSAR trial that assessed Eylea ...

The president threatened to “deploy every tool” in the administration’s arsenal if drug companies don’t cut certain prices by ...

While U.S. President Donald Trump’s country-by-country reciprocal and newly negotiated tariffs go into effect today, a separate, global biopharma sector tariff of, possibly, 200% continues to loom ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

DZ BANK AG analyst Elmar Kraus maintained a Buy rating on Sanofi today. The company’s shares opened today at $91.00. Elevate Your Investing Strategy: Take advantage of TipRanks ...